Clover Biopharmaceuticals Ltd. has announced a proposed change of auditor, with plans to appoint CL Partners as the new auditor following the retirement of EY. The transition, recommended by the Audit Committee, will take effect after the forthcoming Annual General Meeting, pending shareholder approval. The company confirmed no disagreements or issues with EY that require shareholder attention, and expressed gratitude for EY's professional services. The Audit Committee has reviewed CL Partners' credentials and considers them well-qualified for the role.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.